BRIEF—Sun Pharma presents Cequa Restasis switching data

India’s Sun Pharmaceutical Industries has presented Phase IV data on its Cequa (cyclosporine ophthalmic solution) showing sustained improvement in dry eye disease signs and symptoms in patients switched from AbbVie’s Restasis (cyclosporine ophthalmic emulsion) 0.05%.

The presentation at the American Academy of Optometry 2023 showed significant improvements with Cequa for topical ophthalmic use in both corneal fluorescein staining and symptom questionnaire scores starting at four weeks and continuing to 12 weeks.

Lead investigator Josh Johnston, of Georgia Eye Partners in Atlanta, Georgia, said: “By assessing corneal fluorescein staining in all five zones of the cornea, we were able to attain a more complete characterization of corneal health than in many dry eye disease trials, which typically assess only a few corneal areas.”